Aurobindo arm terminates pentavalent vaccine licence pact with Hilleman Labs

Aurobindo Pharma subsidiary Auro Vaccines has terminated a pentavalent vaccine candidate licence agreement with Hilleman Laboratories Singapore.

The September 2023 agreement envisaged developing, manufacturing and commercialising a pentavalent vaccine candidate used in children’s vaccination, Aurobindo Pharma said without sharing reasons for the termination.

Auro Vaccines is not a material subsidiary and termination of the licence agreement for a very early-stage vaccine asset is not a material event. The termination of the agreement will not have any significant impact on the company and/or its subsidiaries or its financials, it said in a filing.

At the time of signing of the agreement, Aurobindo Pharma said Auro Vaccines would make milestone payments to Hilleman upon achieving certain development and clinical-study outcomes. Hilleman would also be paid royalties upon commercialisation of the vaccine candidate.